Macro­Gen­ics ear­marks $580M for ADC tech; Do­mainex, non­prof­it team up on Parkin­son's pro­gram

Synaf­fix and Macro­Gen­ics have signed a deal to code­vel­op and com­mer­cial­ize a clin­i­cal plat­form for an­ti­body-drug con­ju­gates to fight can­cer.

Synaf­fix will li­cense out its Gly­co­Con­nect an­ti­body con­ju­ga­tion plat­form, po­lar spac­er tech­nol­o­gy and toxSYN link­er pay­loads. In re­turn, it will get $586 mil­lion in up­front and mile­stone pay­ments across the three pro­grams and is el­i­gi­ble for roy­al­ties on com­mer­cial sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER